Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 112 of 5804
-
Immunotherapy duo aims to extend lives in advanced bladder cancer
Disease control OngoingThe purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously unt…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New stem cell approach could help more sickle cell patients
Disease control Recruiting nowThe study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant …
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Promising combo therapy shows hope for aggressive breast cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC). After…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy combo shows promise in early lung cancer trial
Disease control CompletedThe purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoin…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New vaccine trial aims to shield frontline workers from deadly mpox
⭐️ VACCINE ⭐️ CompletedMpox is a febrile rash illness caused by the monkeypox virus. Its natural occurrence in the DRC puts healthcare and frontline workers at high risk of acquiring monkeypox virus infections that can prevent them from performing work duties, compromise the overall healthcare delivery…
Phase: PHASE3 • Sponsor: Centers for Disease Control and Prevention • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
Could a single HPV shot slash cervical cancer in africa?
⭐️ VACCINE ⭐️ OngoingCervical cancer is the most common cancer in women aged 15-44 years in East Africa, and mortality rates are very high. HPV vaccines are most effective if given to girls who have not yet acquired HPV infection. In Tanzania, HPV vaccine has been shown to be safe, acceptable and can…
Phase: PHASE3 • Sponsor: London School of Hygiene and Tropical Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 15:56 UTC
-
New hope for stroke prevention: device offers alternative to blood thinners for heart patients
Disease control CompletedThe purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagul…
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising combo offers hope for older AML patients
Disease control OngoingAcute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed. Venetocla…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Radioactive therapy vs. pill: which works better for gut and pancreas tumors?
Disease control OngoingThe purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocri…
Phase: PHASE3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Supercharged immune cells aim to beat back tough leukemia
Disease control OngoingThis is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablati…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on HPV cancers
Disease control CompletedBackground: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells. In this new therapy, researchers take a person's blood, remove certain white blood cells, and insert genes tha…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for aggressive breast cancer: personalized therapy shows promise
Disease control OngoingInvestigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy wi…
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy plus chemo shows promise for tough hodgkin lymphoma
Disease control OngoingThe aim of this study is to improve the chance of cure for people with higher risk Hodgkin lymphoma. The purpose of the Phase I study is to test any good and bad effects of the study drug called Nivolumab when combined with ABVD for the front-line treatment of HL.The purpose of t…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising immunotherapy combo aims to stop deadly childhood cancer's return
Disease control CompletedThe purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side eff…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could breast cancer patients avoid surgery? new trial tests less treatment
Disease control Recruiting nowThis clinical trial studies eliminating surgery and/or radiation therapy in treating breast cancer patients. In HER2 positive and triple negative breast cancers, after systemic therapy, when image-guided biopsy shows no residual cancer, patients then receive standard breast radio…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Keytruda aims to stop Triple-Negative breast cancer return in High-Risk patients
Disease control OngoingThis randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability o…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immunotherapy shows promise as First-Line attack on tough lung cancer
Disease control OngoingThis is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lympho…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged cord blood transplant shows promise in blood cancer trial
Disease control CompletedThis study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid leukemia, m…
Phase: PHASE3 • Sponsor: Gamida Cell ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Brain cancer breakthrough? trial adds radiation during surgery to fight glioblastoma
Disease control OngoingINTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radi…
Phase: PHASE3 • Sponsor: Universitätsmedizin Mannheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New pill combo shows promise in slowing advanced breast cancer
Disease control OngoingThe main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC